Dalbavancin: Difference between revisions
Elcatracho (talk | contribs) |
Elcatracho (talk | contribs) (→Common) |
||
| Line 36: | Line 36: | ||
===Common=== | ===Common=== | ||
*Gastrointestinal: [[Diarrhea]] (Up to 4.4%), Nausea (Up to 5.5%) | |||
*Neurologic: Headache (Up to 4.7%) | |||
==Pharmacology== | ==Pharmacology== | ||
Revision as of 06:20, 7 April 2021
Administration
- Type: Antibiotic
- Dosage Forms: 500 mg/vial; reconstituted concentration 20 mg/ml
- Routes of Administration: Intravenous
- Common Trade Names: Dalvance
Adult Dosing
- 1500 mg as single dose or 1000 mg then 500 mg one week later; infuse over 30 minutes
Pediatric Dosing
- Safety and efficacy not established in pediatric patients
Special Populations
Pregnancy Rating
- Maternal risk cannot be ruled out
Lactation risk
- Fetal risk cannot be ruled out
Renal Dosing
- Adult:
- Pediatric:
Hepatic Dosing
- Adult:
- Pediatric:
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- Gastrointestinal: Clostridium difficile colitis (<2%), Clostridium difficile diarrhea, GI bleed (<2% )
- Hepatic: ALT/SGPT level raised (0.8%)
- Immunologic: Hypersensitivity reaction
Common
- Gastrointestinal: Diarrhea (Up to 4.4%), Nausea (Up to 5.5%)
- Neurologic: Headache (Up to 4.7%)
Pharmacology
- Half-life:
- Metabolism:
- Excretion:
